Advertisement

Infections in Kidney Transplant Recipients

  • Carlos A.Q. Santos
  • Daniel C. Brennan
Chapter

Abstract

Infections are common in recipients of kidney transplants due primarily to immunosuppressive medications prescribed to prevent rejection of the allograft. This chapter describes current strategies for preventing, recognizing, and treating infectious diseases in kidney transplant recipients.

Keywords

Herpes Simplex Virus Respiratory Syncytial Virus Progressive Multifocal Leukoencephalopathy Varicella Zoster Virus Merkel Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998 Jan;11(1):1–26.PubMedGoogle Scholar
  2. 2.
    Little DM, Farrell JG, Cunningham PM, Hickey DP. Donor sepsis is not a contraindication to cadaveric organ donation. QJM 1997 Oct;90(10):641–642.PubMedGoogle Scholar
  3. 3.
    Midtvedt K, Hartmann A, Midtvedt T, Brekke IB. Routine perioperative antibiotic prophylaxis in renal transplantation. Nephrol Dial Transplant 1998 Jul;13(7):1637–1641.CrossRefPubMedGoogle Scholar
  4. 4.
    Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990 Sep;89(3):255–274.CrossRefPubMedGoogle Scholar
  5. 5.
    Seale L, Jones CJ, Kathpalia S et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 1985 Dec 27;254(24):3435–3438.Google Scholar
  6. 6.
    6. Hodson EM, Barclay PG, Craig JC et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2005;(4):CD003774.Google Scholar
  7. 7.
    Lippmann BJ, Brennan DC, Wong J, Lowell JA, Singer GG, Howard TK. Are varicella zoster and herpes simplex sentinel lesions for cytomegalovirus in renal transplant recipients? Lancet 1995 Sep 30;346(8979):914–915.Google Scholar
  8. 8.
    Miller BW, Brennan DC, Korenblat PE, Goss JA, Flye MW. Common variable immunodeficiency in a renal transplant patient with severe recurrent bacterial infection: a case report and review of the literature. Am J Kidney Dis 1995 Jun;25(6):947–951.CrossRefPubMedGoogle Scholar
  9. 9.
    Boggild AK, Sano M, Humar A, Salit I, Gilman M, Kain KC. Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med 2004 Jan–Feb;11(1):37–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Maraha B, Bonten H, van Hooff H, Fiolet H, Buiting AG, Stobberingh EE. Infectious complications and antibiotic use in renal transplant recipients during a 1-year follow-up. Clin Microbiol Infect 2001 Nov;7(11):619–625.CrossRefPubMedGoogle Scholar
  11. 11.
    Koyle MA, Ward HJ, Twomey PA, Glassock RJ, Rajfer J. Declining incidence of wound infection in cadaveric renal transplant recipient. Urology 1988 Feb;31(2):103–106.CrossRefPubMedGoogle Scholar
  12. 12.
    Stephan RN, Munschauer CE, Kumar MS. Surgical wound infection in renal transplantation: outcome data in 102 consecutive patients without perioperative systemic antibiotic coverage. Arch Surg 1997 Dec;132(12):1315–1318;discussion 1318–1319.PubMedGoogle Scholar
  13. 13.
    Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. Infect Dis Clin North Am 1997 Sep;11(3):707–717.CrossRefPubMedGoogle Scholar
  14. 14.
    Abbott KC, Oliver JD 3rd, Hypolite I et al. Hospitalizations for bacterial septicemia after renal transplantation in the united states. Am J Nephrol 2001 Mar–Apr;21(2):120–127.Google Scholar
  15. 15.
    Tveit DJ, Hypolite IO, Poropatich RK et al. Hospitalizations for bacterial pneumonia after renal transplantation in the United States. J Nephrol 2002 May–Jun;15(3):255–262.PubMedGoogle Scholar
  16. 16.
    Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003 Jan;16(1):114–128.CrossRefPubMedGoogle Scholar
  17. 17.
    Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005 Jul;2(7):e164.CrossRefPubMedGoogle Scholar
  18. 18.
    Geel AL, Landman TS, Kal JA, van Doomum GJ, Weimar W. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc 2006 Dec;38(10):3418–3419.CrossRefPubMedGoogle Scholar
  19. 19.
    Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 Jun 22;56(RR-4):1–40.PubMedGoogle Scholar
  20. 20.
    Taylor GS. T cell-based therapies for EBV-associated malignancies. Expert Opin Biol Ther 2004 Jan;4(1):11–21.CrossRefPubMedGoogle Scholar
  21. 21.
    Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004 Jul;66(1):329–337.CrossRefPubMedGoogle Scholar
  22. 22.
    Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001 Nov–Dec;33(7–8):3621–3623.CrossRefPubMedGoogle Scholar
  23. 23.
    Diaz-Pedroche C, Lumbreras C, San Juan R et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006 Jul 15;82(1):30–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005 Jan 15;79(1):85–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008 Mar–Apr;22(2):162–170.CrossRefPubMedGoogle Scholar
  26. 26.
    Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005 Oct 15;192(8):1331–1339.CrossRefPubMedGoogle Scholar
  27. 27.
    Kidd IM, Clark DA, Sabin CA et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000 Jun 15;69(11):2400–2404.CrossRefPubMedGoogle Scholar
  28. 28.
    Schulz TF. Epidemiology of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. Adv Cancer Res 1999;76:121–160.CrossRefPubMedGoogle Scholar
  29. 29.
    Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med 2000 Apr 6;342(14):1027–1038.CrossRefPubMedGoogle Scholar
  30. 30.
    Rao KV, Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996 Dec 27;62(12):1765–1769.CrossRefPubMedGoogle Scholar
  31. 31.
    Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 1991 Feb;51(2):391–396.PubMedGoogle Scholar
  32. 32.
    Mioli VA, Balestra E, Bibiano L et al. Epidemiology of viral hepatitis in dialysis centers: a national survey. Nephron 1992;61(3):278–283.CrossRefPubMedGoogle Scholar
  33. 33.
    Roberts RC, Lane C, Hatfield P et al. All anti-HBc-positive, HBsAg-negative dialysis patients on the transplant waiting list should be regarded as at risk of hepatitis B reactivation post-renal transplantation – report of three cases from a single centre. Nephrol Dial Transplant 2006 Nov;21(11):3316–3319.CrossRefPubMedGoogle Scholar
  34. 34.
    Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999 Jan;29(1):257–263.CrossRefPubMedGoogle Scholar
  35. 35.
    Madayag RM, Johnson LB, Bartlett ST et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997 Dec 27;64(12):1781–1786.CrossRefPubMedGoogle Scholar
  36. 36.
    Han DJ, Kim TH, Park SK et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001 Feb 15;71(3):387–394.CrossRefPubMedGoogle Scholar
  37. 37.
    Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 Mar 9;354(10):1001–1010.CrossRefPubMedGoogle Scholar
  38. 38.
    Boletis JN. Epidemiology and mode of transmission of hepatitis C virus infection after renal transplantation. Nephrol Dial Transplant 2000;15(Suppl 8):52–54.CrossRefPubMedGoogle Scholar
  39. 39.
    Kallinowski B, Hergesell O, Zeier M. Clinical impact of hepatitis C virus infection in the renal transplant recipient. Nephron 2002 Aug;91(4):541–546.CrossRefPubMedGoogle Scholar
  40. 40.
    Anderson LJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J 1987 Aug;6(8):711–718.CrossRefPubMedGoogle Scholar
  41. 41.
    Ardehali H, Volmar K, Roberts C, Forman M, Becker LC. Fatal disseminated adenoviral infection in a renal transplant patient. Transplantation 2001 Apr 15;71(7):998–999.CrossRefPubMedGoogle Scholar
  42. 42.
    Leruez-Ville M, Minard V, Lacaille F et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004 Jan 1;38(1):45–52.CrossRefPubMedGoogle Scholar
  43. 43.
    Ghosh S, Champlin RE, Englund J et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000 Apr;25(7):751–755.CrossRefPubMedGoogle Scholar
  44. 44.
    Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001 Aug 1;184(3):350–354.CrossRefPubMedGoogle Scholar
  45. 45.
    Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 2006;577:19–45.CrossRefPubMedGoogle Scholar
  46. 46.
    Phillips T, Jacobs R, Ellis EN. Polyoma nephropathy and progressive multifocal leukoencephalopathy in a renal transplant recipient. J Child Neurol 2004 Apr;19(4):301–304.CrossRefPubMedGoogle Scholar
  47. 47.
    van Gorder MA, Della Pelle P, Henson JW, Sachs DH, Cosimi AB, Colvin RB. Cynomolgus polyoma virus infection: a new member of the polyoma virus family causes interstitial nephritis, ureteritis, and enteritis in immunosuppressed cynomolgus monkeys. Am J Pathol 1999 Apr;154(4):1273–1284.PubMedGoogle Scholar
  48. 48.
    Bohl DL, Storch GA, Ryschkewitsch C et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005 Sep;5(9):2213–2221.CrossRefPubMedGoogle Scholar
  49. 49.
    Hirsch HH, Knowles W, Dickenmann M et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002 Aug 15;347(7):488–496.CrossRefPubMedGoogle Scholar
  50. 50.
    Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005 Mar;5(3):582–594.CrossRefPubMedGoogle Scholar
  51. 51.
    Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007 Jul;2(Suppl 1):S36–S46.CrossRefPubMedGoogle Scholar
  52. 52.
    Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008 Feb 22;319(5866):1096–1100.CrossRefPubMedGoogle Scholar
  53. 53.
    Lemos B, Nghiem P. Merkel cell carcinoma: more deaths but still no pathway to blame. J Invest Dermatol 2007 Sep;127(9):2100–2103.CrossRefPubMedGoogle Scholar
  54. 54.
    Tharayil John G, Shankar V, Talaulikar G et al. Epidemiology of systemic mycoses among renal-transplant recipients in India. Transplantation 2003 May 15;75(9):1544–1551.CrossRefPubMedGoogle Scholar
  55. 55.
    Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007 Jun;45(6):1735–1745.CrossRefPubMedGoogle Scholar
  56. 56.
    Edwards JE Jr., Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997 Jul;25(1):43–59.CrossRefPubMedGoogle Scholar
  57. 57.
    Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001 May–Jun;7(3):375–381.PubMedGoogle Scholar
  58. 58.
    Bren A, Koselj M, Kandus A et al. Severe fungal infections in kidney graft recipients. Transplant Proc 2002 Nov;34(7):2999–3000.CrossRefPubMedGoogle Scholar
  59. 59.
    Perfect JR, Cox GM, Lee JY et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001 Dec 1;33(11):1824–1833.CrossRefPubMedGoogle Scholar
  60. 60.
    Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 Aug 8;347(6):408–415.CrossRefPubMedGoogle Scholar
  61. 61.
    Nampoory MR, Khan ZU, Johny KV et al. Invasive fungal infections in renal transplant recipients. J Infect 1996 Sep;33(2):95–101.CrossRefPubMedGoogle Scholar
  62. 62.
    Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986 Jan 9;314(2):83–88.CrossRefPubMedGoogle Scholar
  63. 63.
    Spieker C, Barenbrock M, Tepel M, Buchholz B, Rahn KH, Zidek W. Pentamidine inhalation as a prophylaxis against Pneumocystis carinii pneumonia after therapy of acute renal allograft rejection with orthoclone (OKT3). Transplant Proc 1992 Dec;24(6):2602–2603.PubMedGoogle Scholar
  64. 64.
    Koseoglu F, Emiroglu R, Karakayali H, Bilgin N, Haberal M. Prevalence of mycobacterial infection in solid organ transplant recipients. Transplant Proc 2001 Feb–Mar;33(1–2):1782–1784.CrossRefPubMedGoogle Scholar
  65. 65.
    Yildiz A, Sever MS, Turkmen A et al. Tuberculosis after renal transplantation: experience of one Turkish centre. Nephrol Dial Transplant 1998 Jul;13(7):1872–1875.CrossRefPubMedGoogle Scholar
  66. 66.
    Simpson WG, Gerhardstein DC, Thompson JR. Disseminated Strongyloides stercoralis infection. South Med J 1993 Jul;86(7):821–825.CrossRefPubMedGoogle Scholar
  67. 67.
    Berk SL, Verghese A, Alvarez S, Hall K, Smith B. Clinical and epidemiologic features of strongyloidiasis. A prospective study in rural Tennessee. Arch Intern Med 1987 Jul;147(7):1257–1261.CrossRefPubMedGoogle Scholar
  68. 68.
    Lim S, Katz K, Krajden S, Fuksa M, Keystone JS, Kain KC. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 2004 Aug 31;171(5):479–484.PubMedGoogle Scholar
  69. 69.
    Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001 Oct 1;33(7):1040–1047.CrossRefPubMedGoogle Scholar
  70. 70.
    Genta RM. Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. Am J Clin Pathol 1988 Mar;89(3):391–394.PubMedGoogle Scholar
  71. 71.
    Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994 May;169(5):1076–1079.PubMedGoogle Scholar

Copyright information

© Springer-Verlag US 2010

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of MedicineWashington University/Barnes-Jewish Hospital/St. Louis Children’s Hospital ConsortiumSt. LouisUSA
  2. 2.Renal Division, Department of Internal MedicineWashington University School of MedicineSt. LouisUSA

Personalised recommendations